Interim report
Page 1
Interim Report Quarter 3, 2026
Page 2
Stable volumes, resilient profitability and strong cash flow Quarter 3, 2026 • Net sales increased 4.1% to SEK 36,060m (34,638) • Organic sales growth amounted to -0.3%, of which volume accounted for -0.1% and price/mix -0.2%. • EBITA amounted to SEK 3,636m (5,152) • EBITA excl. IAC amounted to SEK 4,725m (5,056) • The EBITA margin excl. IAC amounted to 13.1% (14.6) • ROCE amounted to 11.9% (17.9) and ROCE excl. IAC was 15.5% (17.6) • Profit for the period was SEK 2,346m (3,358) • Earnings per share was SEK 3.47 (4.86) • Operating cash flow amounted to SEK 5,783m (5,324) • Essity has entered into an agreement to acquire Kenvue’s feminine care business in Brazil. The completion of the transaction is expected to close during the second quarter of 2027. -0.3% 13.1% Organic sales growth EBITA margin excl. IAC Financial overview 2026:3 2025:3 % 2609 2509 % Net sales, SEKm 36,060 34,638 4 104,298 103,799 0 Organic sales growth, % -0.3 0.9 0.1 1.7 Gross profit margin, % 30.0 33.5 32.0 33.2 Gross profit margin excl. IAC, % 31.7 33.4 32.6 33.2 EBITA, SEKm 3,636 5,152 -29 12,189 14,498 -16 EBITA margin, % 10.1 14.9 11.7 14.0 EBITA excl. IAC, SEKm 4,725 5,056 -7 14,013 14,455 -3 EBITA margin excl. IAC, % 13.1 14.6 13.4 13.9 Profit for the period, SEKm 2,346 3,358 -30 7,940 9,494 -16 Earnings per share, SEK 3.47 4.86 -29 11.65 13.68 -15 Earnings per share*, SEK 4.92 5.01 -2 14.44 14.37 0 ROCE, % 11.9 17.9 14.7 16.8 ROCE excl. IAC, % 15.5 17.6 16.4 17.1 Operating cash flow, SEKm 5,783 5,324 9 12,927 10,629 22 Net debt/EBITDA excl. IAC 0.98 1.18 * Earnings per share excl. IAC and amortization of acquisition-related intangible assets Essity Aktiebolag (publ) Interim Report Quarter 3, 2026 1
Page 3
CEO’s comments Essity’s development in the third quarter was characterized by stability and resilience in a challenging market. Profitability remained good despite intensifying cost headwinds, and cash flow was strong. Volumes were stable, and we strengthened our market positions in several strategic segments, demonstrating the competitiveness of our business. At the same time, the Group’s sales development was not at the level we are aiming for, and we continue our efforts to accelerate profitable growth and offset higher costs through price increases and efficiency improvements. Cost savings were delivered according to plan, investments in marketing and customer offerings are yielding results, and sales prices were higher than in the second quarter of this year. Demonstrated strength across several categories Health & Medical delivered organic growth and good profitability during the quarter. Incontinence Products continued to grow, and the sales development in Medical Solutions was positive, with good growth in wound care. Sales in Personal Care also performed well, supported by continued high growth and increased market shares in Incontinence Products and Feminine Care. Consumer Tissue had lower sales due to lower volumes, primarily driven by optimization of the production footprint in Latin America, and price reductions in previous quarters. In Professional Hygiene, profitability remained solid, although volume development was not satisfactory. The decline was concentrated to the base assortment and smaller distributors which were more affected by the weaker market. However, we continued to grow in strategic products and increased sales to our larger distributors and customers. Product launches and price increases During the quarter, we launched new and improved products across several categories to further strengthen our offering. For example, we expanded our range of compression garments with JOBST® Elvarex® Soft ready-to-wear, allowing us to reach patients more quickly. We continued to actively work on price increases to offset higher costs, and all business areas reported higher sales prices compared with the second quarter. “Our focus is on translating strong market positions into profitable growth” Another acquisition in feminine care During the quarter, we took another step forward in our strategy to grow in attractive, value-creating categories by entering into an agreement to acquire Kenvue’s feminine care business in Brazil. The acquisition includes the market-leading brands Carefree, Sempre Livre and o.b., and strengthens Essity’s position in feminine care in Latin America. Brazil represents a significant growth opportunity in hygiene and health, where we already hold a leading position in incontinence products with TENA. This acquisition follows our previous feminine care acquisition in North America and represents another concrete step in the expansion of our feminine care business, where we have a proven track record of success and see good potential for profitable growth. The transaction is subject to regulatory approval and is expected to close in the second quarter of 2027. Strategic review of Consumer Tissue The strategic review of Consumer Tissue is proceeding according to plan. We have assessed the conditions for a separation and are now ready to move forward with evaluating the value creation potential of the different strategic alternatives - a separation or Consumer Tissue remaining part of Essity. The ambition is to identify the alternative that provides the best opportunity for both Consumer Tissue and Essity to reach their full potential and maximize long-term value creation. Focus on higher growth Our focus is on translating strong market positions into profitable growth. We continue to prioritize investments where we see the greatest opportunities to grow and create value, while improving efficiency and addressing increasing cost headwinds through pricing and cost measures. In parallel, we continue to develop our portfolio. We have clear priorities and will now ensure that our initiatives have a greater impact on the Group’s growth and profitability. Ulrika Kolsrud President and CEO Essity Aktiebolag (publ) Interim Report Quarter 3, 2026 2
Page 4
Group Net sales Net sales increased 4.1% in the third quarter of 2026 compared with the corresponding period a year ago and amounted to SEK 36,060m (34,638). The acquisition in Feminine Care in North America increased the Group's consolidated net sales by 1.9%. Organic sales decreased 0.3%, primarily as a result of price reductions in previous quarters. Sales prices were higher in the quarter compared with the second quarter across all business areas. The product mix developed positively and volumes were stable. Growth was positive in North America, with a high growth in both Health & Medical and Personal Care. In Europe and Latin America, organic sales were slightly lower, primarily due to reduced sales in Consumer Tissue. Change in net sales % 2026:3 vs 2025:3 Total 4.1 Volume -0.1 Price/Mix -0.2 Organic growth -0.3 Acquisitions 1.9 Divestments 0.0 Currency translation 2.5 Operating profit The gross profit margin amounted to 30.0% (33.5). The gross profit margin excl. IAC amounted to 31.7% (33.4). Costs of goods sold were higher, mainly due to increased costs for raw materials and energy. Savings in costs of goods sold amounted to approximately SEK 180m. EBITA amounted to SEK 3,636m (5,152) and EBITA excl. IAC amounted to SEK 4,725m (5,056). The EBITA margin excl. IAC amounted to 13.1% (14.6). Sales and administration costs amounted to 18.6% (18.8), of which marketing costs amounted to 5.2% (5.2). Cost savings in sales and administration amounted to approximately SEK 150m. IAC amounted to SEK -1,089m (96), of which approximately SEK 450m was attributable to the cost savings program and approximately SEK 500m to optimization of the production footprint in Consumer Tissue in Latin America. Change in EBITA excl. IAC SEKm EBITA excl. IAC 2025:3 5,056 Volume 80 Price/Mix -77 Cost of goods sold -658 Sales & Admin 148 Currency translation 163 Acquisitions & Divestments 13 EBITA excl. IAC 2026:3 4,725 Net sales 2609 by business area 20% 25% 30% 25% Health & MedicalPersonal CareConsumer TissueProfessional Hygiene Net sales 2609 by region 59% 18% 17% 6% Europe Latin America North AmericaOther Net sales SEKm % Net sales Organic sales growth % 2024:32024:42025:12025:22025:32025:42026:12026:22026:3 20,000 25,000 30,000 35,000 40,000 -2 0 2 4 6 EBITA excl. IAC SEKm % EBITA excl. IAC EBITA margin excl. IAC % 2024:32024:42025:12025:22025:32025:42026:12026:22026:3 2,000 3,000 4,000 5,000 6,000 10 12 14 16 18 Essity Aktiebolag (publ) Interim Report Quarter 3, 2026 3
Page 5
Financial items Financial items decreased to SEK -275m (-369), on account of lower interest rates and lower average net debt. Tax The tax expense was SEK 749m (1,178), corresponding to a tax rate of 24.2% (26.0). The tax expense excl. IAC was SEK 1,044m (1,151), corresponding to a tax rate of 25.0% (25.9). Profit for the period Profit for the period was SEK 2,346m (3,358). Cash flow Operating cash flow amounted to SEK 5,783m (5,324). The increase compared with a year ago was mainly related to more favorable development in working capital, which was partly offset by higher payments for restructuring costs. Net cash flow totaled SEK 3,621m (2,933). During the quarter, Essity bought back 4,101,510 own Class B shares for a total amount of SEK 1,117m. Operating cash flow statement SEKm 2026:3 2025:3 2609 2509 Operating cash surplus 6,635 6,757 19,417 19,484 Change in inventories 56 -8 -673 -1,622 Change in operating receivables 464 772 -1,529 79 Change in operating liabilities 752 -364 1,813 -1,726 Investments in non-current assets, net -1,506 -1,657 -4,244 -4,438 Restructuring costs, etc. -513 -67 -1,423 -575 Investments in operating assets through leases -105 -109 -434 -573 Operating cash flow 5,783 5,324 12,927 10,629 Financial items -275 -369 -832 -1,075 Income taxes paid -770 -873 -3,094 -3,460 Other — — 16 27 Cash flow from current operations 4,738 4,082 9,017 6,121 Acquisitions of Group companies and other operations — ─ -3,087 ─ Divestments of Group companies and other operations — 5 — 5 Cash flow before transactions with shareholders 4,738 4,087 5,930 6,126 Dividend — — -5,956 -5,711 Dividend to non-controlling interests — -7 — -11 Repurchase of own shares -1,117 -1,147 -2,283 -2,605 Net cash flow 3,621 2,933 -2,309 -2,201 Operating cash flow SEKm 2024:32024:4 2025:1 2025:2 2025:32025:4 2026:1 2026:22026:3 1,000 2,000 3,000 4,000 5,000 6,000 7,000 Essity Aktiebolag (publ) Interim Report Quarter 3, 2026 4
Page 6
Financial position Net debt decreased SEK 1,591m compared with December 31, 2025 and amounted to SEK 24,952m. The decrease is mainly related to revaluation of pension assets and pension obligations. Net cash flow increased net debt by SEK 2,309m. The Group’s interest-bearing gross debt amounted to SEK 35,208m (35,187) at the end of the quarter. The average maturity period was 2.6 years (3.6). Compared with December 31, 2025, working capital increased to SEK 15,304m, mainly due to higher valuation of energy derivatives and increased trade receivables. Working capital amounted to 10.6% (9.2) of net sales. Share buyback program Between July 1 and September 30, 2026, Essity bought back 4,101,510 own Class B shares for a total amount of SEK 1,117m. The buybacks are part of the buyback program for SEK 3bn that Essity announced on April 22, 2026. The buyback program extends from May 12, 2026 until the 2027 Annual General Meeting at the latest. As of September 30, 2026, Essity’s holdings of own shares amounted to 7,458,875, corresponding to 1.1% of the total number of shares. Repurchased shares are expected to be canceled. The buybacks will be financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity’s capital allocation. Net debt SEKm Net debt Net debt/ EBITDA excl. IAC 2409 2412 2503 2506 2509 2512 2603 2606 2609 0 10,000 20,000 30,000 40,000 0 1 2 3 4 Financial position 2609 2509 2512 Working capital, SEKm 15,304 12,816 12,237 Capital employed, SEKm 122,588 114,289 112,583 Net debt, SEKm 24,952 30,306 26,543 Debt/equity ratio 0.26 0.36 0.31 Debt payment capacity, % 74 60 74 Net debt/EBITDA 1.04 1.20 1.03 Net debt/EBITDA excl. IAC 0.98 1.18 1.03 Change in net debt SEKm 2609 2509 2512 Net debt at the beginning of the period -26,543 -30,769 -30,769 Net cash flow -2,309 -2,201 42 Remeasurements to equity 5,371 1,208 2,423 Investments in non-operating assets through leases -202 -207 -331 Translation differences -1,269 1,663 2,092 Net debt at the end of the period -24,952 -30,306 -26,543 ROCE excl. IAC and ROE excl. IAC % ROCE excl. IAC ROE excl. IAC 2024:32024:4 2025:1 2025:22025:32025:4 2026:12026:22026:3 10 12 14 16 18 20 Return % 2026:3 2025:3 2609 2509 ROCE 11.9 17.9 14.7 16.8 ROCE excl. IAC 15.5 17.6 16.4 17.1 ROE 9.8 16.3 12.4 14.8 ROE excl. IAC 13.2 15.9 14.1 15.2 Essity Aktiebolag (publ) Interim Report Quarter 3, 2026 5
Page 7
Health & Medical Net sales Net sales increased organically by 1.2%, driven by higher sales prices. Growth was high in North America, while sales were stable in Europe and declined in Latin America. In Incontinence Products, both higher volumes and sales prices supported organic growth. Higher sales prices were the main driver for Medical Solutions, with good growth noted in wound care. EBITA excl. IAC EBITA and the EBITA margin excl. IAC were higher. Earnings were positively impacted by higher sales prices and lower sales and administration costs. Costs of goods sold were higher. Currency translation effects impacted earnings positively by SEK 22m. With its five new models and standard sizes, JOBST® Elvarex® Soft now offers a comprehensive product range, making it easier for patients to find the right fit. Change in net sales % 2026:3 vs 2025:3 Total 2.7 Volume -0.1 Price/Mix 1.3 Organic growth 1.2 Acquisitions 0.0 Divestments 0.0 Currency translation 1.5 Organic sales growth % 2026:3 vs 2025:3 % of net sales Incontinence Products Health Care 1.5 57 Medical Solutions 0.7 43 Financial overview 2026:3 2025:3 % Net sales, SEKm 7,066 6,883 3 Organic sales growth, % 1.2 1.7 Gross profit margin excl. IAC, % 43.2 43.8 EBITA excl. IAC, SEKm 1,302 1,260 3 EBITA margin excl. IAC, % 18.4 18.3 ROCE excl. IAC, % 15.6 15.3 Operating cash flow, SEKm 1,657 1,471 13 Net sales 2609 by region 66% 17% 6% 11% Europe North America Latin America Other Net sales SEKm % Net sales Organic sales growth % 2024:32024:42025:12025:22025:32025:42026:12026:22026:3 0 2,000 4,000 6,000 8,000 -4 0 4 8 12 EBITA excl. IAC SEKm % EBITA excl. IAC EBITA margin excl. IAC % 2024:32024:42025:12025:22025:32025:42026:12026:22026:3 0 500 1,000 1,500 16 18 20 22 Essity Aktiebolag (publ) Interim Report Quarter 3, 2026 6 • Higher prices and stable volumes • High growth in North America • Higher EBITA and margin, excl. IAC
Page 8
Personal Care Net sales Net sales increased organically by 3.2%, primarily driven by good volume growth. The product mix was also favorable, while sales prices were lower. Market shares increased for branded sales. Growth was high in North America and Latin America, while sales were stable in Europe. Incontinence Products and Feminine Care reported high organic growth, primarily due to strong volume growth, and strengthened their market shares during the quarter. In Baby Care, volumes were negatively impacted by a shrinking market, while the market positions of the leading brand, Libero, were further strengthened. EBITA excl. IAC EBITA excl. IAC increased, while the EBITA margin excl. IAC decreased. Earnings were positively impacted by higher volumes and negatively impacted by lower sales prices, higher costs of goods sold, sales and marketing as well as temporary integration costs related to the acquisition in Feminine Care in North America. Currency translation effects had a positive impact on earnings of SEK 88m. The upgraded Saba Ultra Thin Night Pads combine our patented SmartProtect™ absorption technology with a wider absorbent core and an ultra-soft topsheet, providing superior protection, enhanced comfort, and peace of mind all night long. Change in net sales % 2026:3 vs 2025:3 Total 16.1 Volume 3.1 Price/Mix 0.1 Organic growth 3.2 Acquisitions 8.2 Divestments 0.0 Currency translation 4.7 Organic sales growth % 2026:3 vs 2025:3 % of net sales Incontinence Products Retail 5.1 34 Feminine Care 5.6 48 Baby Care -3.9 18 Financial overview 2026:3 2025:3 % Net sales, SEKm 9,205 7,927 16 Organic sales growth, % 3.2 4.5 Gross profit margin excl. IAC, % 39.6 40.9 EBITA excl. IAC, SEKm 1,241 1,110 12 EBITA margin excl. IAC, % 13.5 14.0 ROCE excl. IAC, % 21.5 24.0 Operating cash flow, SEKm 1,610 1,133 42 Net sales 2609 by region 44% 35% 15% 6% Europe Latin America North America Other Net sales SEKm % Net sales Organic sales growth, % 2024:32024:42025:12025:22025:32025:42026:12026:22026:3 2,000 4,000 6,000 8,000 10,000 -4 0 4 8 12 EBITA excl. IAC SEKm % EBITA excl. IAC EBITA margin excl. IAC % 2024:32024:42025:12025:22025:32025:42026:12026:22026:3 0 500 1,000 1,500 2,000 10 12 14 16 18 Essity Aktiebolag (publ) Interim Report Quarter 3, 2026 7 • Higher volumes and market shares • High growth in North America and Latin America • High growth in Incontinence Products and Feminine Care
Page 9
Consumer Tissue Net sales Net sales decreased organically by 3.0% due to lower volumes, mainly driven by optimization of the production footprint in Latin America, as well as lower sales prices related to price adjustments in previous quarters. Sales prices were higher compared with the second quarter. Sales declined in both Europe and Latin America. EBITA excl. IAC EBITA and the EBITA margin excl. IAC decreased, mainly due to higher costs of goods sold, but also lower sales prices and volumes had a negative impact. Sales and administration costs were lower. Currency translation effects had a positive impact on earnings of SEK 39m. Regio Luxury Almond Touch has been upgraded with Ultimate Touch™, featuring superior softness, new embossing, clearer product benefits and an exclusive design, strengthening the brand’s competitiveness in the premium segment. Change in net sales % 2026:3 vs 2025:3 Total -1.1 Volume -1.9 Price/Mix -1.1 Organic growth -3.0 Acquisitions 0.0 Divestments 0.0 Currency translation 1.9 Financial overview 2026:3 2025:3 % Net sales, SEKm 10,541 10,656 -1 Organic sales growth, % -3.0 -1.9 Gross profit margin excl. IAC, % 18.1 21.8 EBITA excl. IAC, SEKm 908 1,252 -27 EBITA margin excl. IAC, % 8.6 11.7 ROCE excl. IAC, % 9.9 14.1 Operating cash flow, SEKm 502 947 -47 Net sales 2609 by region 78% 20% 2% Europe Latin America Other Net sales SEKm % Net sales Organic sales growth, % 2024:32024:42025:12025:22025:32025:42026:12026:22026:3 6,000 8,000 10,000 12,000 14,000 -8 -4 0 4 8 EBITA excl. IAC SEKm % EBITA excl. IAC EBITA margin excl. IAC % 2024:32024:42025:12025:22025:32025:42026:12026:22026:3 0 500 1,000 1,500 2,000 6 8 10 12 14 Essity Aktiebolag (publ) Interim Report Quarter 3, 2026 8 • Lower volumes and sales prices • Ongoing price increases, with sequentially higher prices
Page 10
Professional Hygiene Net sales Net sales decreased organically by 1.1%, due to lower volumes, mainly in the base assortment, and lower sales prices. The product mix remained favorable with an increased share of premium products. Sales declined in North America and Europe, while remaining stable in Latin America. EBITA excl. IAC EBITA and the EBITA margin excl. IAC decreased, mainly due to lower prices and higher costs of goods sold. Sales and administration costs were lower. Currency translation effects had a positive impact on earnings of SEK 32m. Tork Vision Cleaning enables data-driven cleaning through connected dispensers, people counting and real-time analytics, helping customers optimize cleaning resources, ensure product availability and enhance operational efficiency. Change in net sales % 2026:3 vs 2025:3 Total 0.8 Volume -0.6 Price/Mix -0.5 Organic growth -1.1 Acquisitions 0.0 Divestments 0.0 Currency translation 1.9 Financial overview 2026:3 2025:3 % Net sales, SEKm 9,257 9,183 1 Organic sales growth, % -1.1 0.7 Gross profit margin excl. IAC, % 30.8 32.5 EBITA excl. IAC, SEKm 1,575 1,676 -6 EBITA margin excl. IAC, % 17.0 18.3 ROCE excl. IAC, % 23.2 26.2 Operating cash flow, SEKm 2,160 1,880 15 Net sales 2609 by region 46% 40% 9% 5% Europe North America Latin America Other Net sales SEKm % Net sales Organic sales growth, % 2024:32024:42025:12025:22025:32025:42026:12026:22026:3 4,000 6,000 8,000 10,000 12,000 -8 -4 0 4 8 EBITA excl. IAC, SEKm SEKm % EBITA excl. IAC EBITA margin excl. IAC % 2024:32024:42025:12025:22025:32025:42026:12026:22026:3 0 500 1,000 1,500 2,000 12 14 16 18 20 Essity Aktiebolag (publ) Interim Report Quarter 3, 2026 9 • Lower sales prices • Lower volumes in the base assortment • Growth in premium products
Page 11
First nine months 2026 Net sales Net sales increased 0.5% compared with the corresponding period a year ago and amounted to SEK 104,298m (103,799). Excluding currency translation effects, net sales increased SEK 1,778m. Sales increased organically by 0.1%. Higher volumes in Health & Medical, Personal Care and Professional Hygiene compensated for lower sales prices, mainly attributable to Consumer Tissue. The product mix was positive for the Group. Operating profit The gross profit margin amounted to 32.0% (33.2). The gross profit margin excl. IAC was 32.6% (33.2). Higher volumes and a positive product mix largely offset lower sales prices. Costs of goods sold were higher. Savings in costs of goods sold totaled approximately SEK 460m. EBITA decreased 16% to SEK 12,189m (14,498), and EBITA excl. IAC decreased 3% to SEK 14,013m (14,455). Excluding currency translation effects, EBITA excl. IAC decreased 2%. The EBITA margin excl. IAC amounted to 13.4% (13.9). Sales and administration costs decreased and amounted to 19.1% (19.3), of which marketing costs accounted for 5.3% (5.2). Cost savings amounted to approximately SEK 280m. IAC totaled SEK -1,831m (62), of which approximately SEK 1,100m was attributable to the cost savings program and approximately SEK 500m to optimization of the production footprint in Consumer Tissue in Latin America. Financial items Financial items decreased to SEK -832m (-1,075), due to lower interest rates and lower average net debt. Tax The tax expense was SEK 2,673m (3,217),corresponding to a tax rate of 25.2% (25.3). The tax expense excl. IAC was SEK 3,151m (3,197), corresponding to a tax rate of 25.3% (25.3). Profit for the period Profit for the period was SEK 7,940m (9,494). Group 2609 2509 % Net sales, SEKm 104,298 103,799 0 Organic sales growth, % 0.1 1.7 Gross profit margin excl. IAC, % 32.6 33.2 EBITA excl. IAC, SEKm 14,013 14,455 -3 EBITA margin excl. IAC, % 13.4 13.9 ROCE excl. IAC, % 16.4 17.1 Operating cash flow, SEKm 12,927 10,629 22 Health & Medical 2609 2509 % Net sales, SEKm 20,483 20,542 0 Organic sales growth, % 1.6 1.1 Gross profit margin excl. IAC, % 44.3 44.0 EBITA excl. IAC, SEKm 3,805 3,650 4 EBITA margin excl. IAC, % 18.6 17.8 ROCE excl. IAC, % 15.6 15.1 Operating cash flow, SEKm 3,609 3,101 16 Personal Care 2609 2509 % Net sales, SEKm 26,200 23,674 11 Organic sales growth, % 3.7 3.7 Gross profit margin excl. IAC, % 40.6 41.8 EBITA excl. IAC, SEKm 3,634 3,428 6 EBITA margin excl. IAC, % 13.9 14.5 ROCE excl. IAC, % 21.9 25.6 Operating cash flow, SEKm 3,264 2,002 63 Consumer Tissue 2609 2509 % Net sales, SEKm 31,099 32,628 -5 Organic sales growth, % -3.9 1.2 Gross profit margin excl. IAC, % 19.4 21.4 EBITA excl. IAC, SEKm 3,008 3,745 -20 EBITA margin excl. IAC, % 9.7 11.5 ROCE excl. IAC, % 12.5 13.5 Operating cash flow, SEKm 2,375 2,895 -18 Professional Hygiene 2609 2509 % Net sales, SEKm 26,523 26,943 -2 Organic sales growth, % 1.0 0.7 Gross profit margin excl. IAC, % 31.1 31.8 EBITA excl. IAC, SEKm 4,459 4,614 -3 EBITA margin excl. IAC, % 16.8 17.1 ROCE excl. IAC, % 23.7 25.3 Operating cash flow, SEKm 4,064 3,424 19 Essity Aktiebolag (publ) Interim Report Quarter 3, 2026 10
Page 12
Other Group information Sustainability Sustainability is integrated into Essity’s strategy and is a priority, with ambitious Group targets in several areas. The outcome for two of the targets is presented below. More information on these and other targets can be found in Essity’s Annual Report. Science-based emissions targets: 2030 Target: -35% vs 2016 Reduction in absolute greenhouse gas emissions, Scope 1 and 2 2022 2023 2024 2025 9M 2026* -17% -27% -27% -27% -30% *Outcome for the last 12 months Sustainable innovations: Target: >50% annually Percentage leading to social and/or environmental improvements 2022 2023 2024 2025 9M 2026 68% 85% 87% 80% 76% Events during the quarter Essity appoints Andreas Mattsson as new Chief Legal Officer On July 7, Essity announced that it had appointed Andreas Mattsson as the new Chief Legal Officer and member of the company’s Executive Management Team. He succeeds Mikael Schmidt who has decided to retire as of December 31, 2026. Andreas Mattsson comes from the role of General Counsel at Billerud, and will take office on January 1, 2027. He will also be responsible for compliance and risk management at Essity. Essity acquires feminine care business in Brazil On August 19, Essity announced that it had entered into an agreement to acquire Kenvue’s feminine care business in Brazil, including the market-leading brands Carefree, Sempre Livre and o.b. The acquisition strengthens Essity’s position as a market leader in feminine care in Latin America. The transaction is expected to close during the second quarter of 2027. Essity’s CFO to retire during 2027 On September 21, Essity announced that Fredrik Rystedt, following more than nine years as CFO and Executive Vice President at the company, had informed the company of his wish to retire during 2027. The process of appointing a successor is ongoing and Fredrik Rystedt will remain in his current role until a successor has been appointed and an orderly handover has been completed. Stockholm, October 22, 2026 Essity Aktiebolag (publ) Ulrika Kolsrud President and CEO Essity Aktiebolag (publ) Interim Report Quarter 3, 2026 11 NB: This information is such that Essity Aktiebolag (publ) is obligated to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. This report has been prepared in both Swedish and English versions. In case of variations in the content between the two versions, the Swedish version shall govern. The information was submitted for publication, through the agency of Karl Stoltz, Public Relations Director, at 07:00 CET on October 22, 2026. This report has not been reviewed by the company’s auditors.
Page 13
Financial statements Condensed consolidated income statement SEKm 2026:3 2025:3 % 2609 2509 % Net sales 36,060 34,638 4 104,298 103,799 0 Cost of goods sold -24,618 -23,065 -70,326 -69,351 Items affecting comparability (IAC) - cost of goods sold -608 25 -583 3 Gross profit 10,834 11,598 -7 33,389 34,451 -3 Gross profit excl. IAC 11,442 11,573 -1 33,972 34,448 -1 Sales, general and administration -6,717 -6,517 -19,959 -19,993 Items affecting comparability (IAC) - sales, general and administration -481 71 -1,241 40 Operating profit before amortization of acquisition-related intangible assets (EBITA) 3,636 5,152 -29 12,189 14,498 -16 Operating profit before amortization of acquisition-related intangible assets (EBITA) excl. IAC 4,725 5,056 -7 14,013 14,455 -3 Amortization of acquisition-related intangible assets -267 -243 -771 -740 Items affecting comparability (IAC) - acquisition- related intangible assets — — -7 19 Operating profit 3,369 4,909 -31 11,411 13,777 -17 Operating profit excl. IAC 4,458 4,813 -7 13,242 13,715 -3 Share of results of associates and joint ventures 1 -4 34 9 Financial items -275 -369 -832 -1,075 Profit before tax 3,095 4,536 -32 10,613 12,711 -17 Profit before tax excl. IAC 4,184 4,440 -6 12,444 12,649 -2 Income taxes -749 -1,178 -2,673 -3,217 Profit for the period 2,346 3,358 -30 7,940 9,494 -16 Profit for the period excl. IAC 3,140 3,289 -5 9,293 9,452 -2 Items affecting comparability (IAC) before tax -1,089 96 -1,831 62 Items affecting comparability (IAC) after tax -794 69 -1,353 42 Tax on amortization of acquisition-related intangible assets 77 72 223 218 SEKm 2026:3 2025:3 2609 2509 Earnings attributable to: Owners of the Parent company 2,346 3,341 7,914 9,448 Non-controlling interests 0 17 26 46 Profit for the period 2,346 3,358 7,940 9,494 Earnings per share -Owners of the Parent company Earnings per share before and after dilution effects, SEK 3.47 4.86 11.65 13.68 Average numbers of shares before and after dilution effects, million 677 687 680 691 Essity Aktiebolag (publ) Interim Report Quarter 3, 2026 12
Page 14
Consolidated statement of comprehensive income SEKm 2026:3 2025:3 % 2609 2509 % Profit for the period 2,346 3,358 -12 7,940 9,494 -9 Other comprehensive income for the period Items that will not be reclassified to the income statement Actuarial gains/losses on defined benefit pension plans 380 795 5,370 1,206 Fair value through other comprehensive income -2 2 1 2 Income tax attributable to components in other comprehensive income -89 -192 -1,233 -307 Total 289 605 4,138 901 SEKm 2026:3 2025:3 2609 2509 Items that have been or may be reclassified subsequently to the income statement Cash flow hedges: Result from remeasurement of derivatives recognized in equity 959 -72 1,586 -556 Transferred to profit or loss for the period -129 35 -69 109 Translation differences in foreign operations 2,481 -710 6,981 -8,257 Gains/losses from hedges of net investments in foreign operations -226 341 -374 1,722 Income tax attributable to components in other comprehensive income -156 -58 -297 -258 Total 2,929 -464 7,827 -7,240 Other comprehensive income for the period, net of tax 3,218 141 11,965 -6,339 Total comprehensive income for the period 5,564 3,499 19,905 3,155 Total comprehensive income attributable to: Owners of the Parent company 5,547 3,484 19,829 3,154 Non-controlling interests 17 15 76 1 Essity Aktiebolag (publ) Interim Report Quarter 3, 2026 13
Page 15
Consolidated balance sheet SEKm Sep 30, 2026 Sep 30, 2025 Dec 31, 2025 ASSETS Non-current assets Goodwill 40,342 37,614 36,861 Intangible assets 19,185 18,818 18,273 Property, plant and equipment 50,094 46,130 46,308 Right-of-use assets 3,784 3,807 3,752 Investments in associates and joint ventures 341 311 307 Shares and participations 8 8 8 Surplus in funded pension plans 9,726 3,489 4,340 Non-current financial assets 129 124 142 Deferred tax assets 2,163 2,279 2,122 Other non-current assets 1,077 747 725 Total non-current assets 126,849 113,327 112,838 Current Assets Inventories 20,642 19,193 18,153 Trade receivables 24,109 22,425 21,332 Current tax assets 1,805 1,373 1,626 Other current receivables 5,014 3,569 3,414 Current financial assets 1,021 1,491 1,266 Non-current assets held for sale 24 13 ─ Cash and cash equivalents 5,537 6,229 8,487 Total current assets 58,152 54,293 54,278 Total assets 185,001 167,620 167,116 SEKm Sep 30, 2026 Sep 30, 2025 Dec 31, 2025 EQUITY AND LIABILITIES Equity Owners of the Parent company Share capital 2,350 2,350 2,350 Reserves 12,050 6,035 4,257 Retained earnings including profit/loss for the period 82,801 75,181 79,018 Equity attributable to owner of the Parent company 97,201 83,566 85,625 Non-controlling interests 435 417 415 Total equity 97,636 83,983 86,040 Non-current liabilities Non-current financial liabilities 25,372 32,011 31,386 Provisions for pensions 2,129 2,438 2,146 Deferred tax liabilities 7,832 6,588 6,272 Other non-current provisions 496 410 384 Other non-current liabilities 20 101 92 Total non-current liabilities 35,849 41,548 40,280 Current liabilities Current financial liabilities 13,864 7,190 7,246 Trade payables 16,304 14,672 14,437 Current tax liabilities 1,794 1,501 1,847 Current provisions 1,465 982 1,200 Other current liabilities 18,089 17,744 16,066 Total current liabilities 51,516 42,089 40,796 Total equity and liabilities 185,001 167,620 167,116 Essity Aktiebolag (publ) Interim Report Quarter 3, 2026 14
Page 16
Consolidated statement of change in equity SEKm Sep 30, 2026 Sep 30, 2025 Dec 31, 2025 Equity attributable to owners of the Parent company Value, beginning of the period 85,625 88,314 88,314 Total comprehensive income for the period 19,829 3,154 5,734 Dividend -5,956 -5,711 -5,711 Buyback of own shares -2,283 -2,605 -3,160 Transferred to cost of hedged investments 14 5 6 Acquisition of non-controlling interest -28 ─ ─ Revaluation effect upon acquisition of non-controlling interests ─ 409 442 Value, end of period 97,201 83,566 85,625 Non-controlling interests Value, beginning of period 415 427 427 Total comprehensive income for the period 76 1 8 Dividend ─ -11 -20 Acquisition of non-controlling interests -56 ─ ─ Value, end of period 435 417 415 Total equity, value end of period 97,636 83,983 86,040 Essity Aktiebolag (publ) Interim Report Quarter 3, 2026 15
Page 17
Consolidated cash flow statement SEKm 2609 2509 Operating activities Operating profit 11,411 13,777 A d j u s t m e n t s f o r n o n - c a s h i t e m s ¹ ⁾ 7,365 5,770 Capitalized expenditures to fulfill contracts with customers -450 -362 Change in provisions relating to restructuring programs, etc. -315 -249 Cash flow from changes in working capital Change in inventories -673 -1,622 Change in operating receivables -1,529 79 Change in operating liabilities 1,813 -1,726 Cash flow from operations 17,622 15,667 Interest paid -1,431 -2,450 Interest received 164 217 Other financial items -94 -57 Income taxes paid -3,094 -3,460 Cash flow from operating activities 13,167 9,917 Investing activities Acquisitions of Group companies and other operations -2,994 ─ Divestments of Group companies and other operations — 5 Investments in intangible assets and property, plant and equipment -4,313 -4,630 Paid interest capitalized in intangible assets and property, plant and equipment -13 -9 Sale of property, plant and equipment 81 202 Purchase and sale of financial assets with short maturities 902 3,814 Cash flow from investing activities -6,337 -618 SEKm 2609 2509 Financing activities Acquisition of non-controlling interests -83 — Proceeds from borrowings 6,409 886 Repayment of borrowings -9,028 -5,056 Payment of lease liabilities -820 -816 Change in borrowings with short maturities, etc. 1,733 -464 Dividend -5,956 -5,711 Dividend to non-controlling interests — -11 Repurchase of own shares -2,283 -2,605 Cash flow from financing activities -10,028 -13,777 Cash flow for the period -3,198 -4,478 Cash and cash equivalents at the beginning of the period 8,487 10,962 Translation differences in cash and cash equivalents 248 -255 Cash and cash equivalents at the end of the period 5,537 6,229 ¹ ⁾ A d j u s t m e n t s f o r n o n - c a s h i t e m s SEKm 2609 2509 Depreciation/amortization and impairment of non-current assets 5,924 5,296 Depreciation of capitalized selling expenses 350 341 Gain/loss on sale of assets 14 -67 Gain/loss on divestment and liquidation — 2 Non-cash items relating to restructuring program 662 79 Other 415 119 Total 7,365 5,770 Essity Aktiebolag (publ) Interim Report Quarter 3, 2026 16
Page 18
Consolidated cash flow statement, cont. Reconciliation with consolidated operating cash flow statement SEKm 2609 2509 Cash flow for the period -3,198 -4,478 Proceeds from borrowings -6,409 -886 Repayment of borrowings 9,028 5,056 Payment of lease liabilities 820 816 Change in borrowings with short maturities, etc. -1,733 464 Purchase and sale of financial assets with short maturities -902 -3,814 Net debt in acquired and divested operations -10 ─ Investments in operating assets through leases -434 -573 Accrued interest, etc. 529 1,214 Net cash flow according to consolidated operating cash flow statement -2,309 -2,201 Essity Aktiebolag (publ) Interim Report Quarter 3, 2026 17
Page 19
Condensed financial statements, Parent company Condensed Parent company income statement SEKm 2609 2509 Administrative expenses -735 -688 Other operating income 278 183 Operating loss -457 -505 Financial items -568 12,185 Profit/loss before tax -1,025 11,680 Income taxes 65 90 Profit/loss for the period -960 11,770 Parent company statement of comprehensive income SEKm 2609 2509 Profit/loss for the period -960 11,770 Other comprehensive income for the period ─ ─ Total comprehensive income for the period -960 11,770 Condensed Parent company balance sheet SEKm Sep 30, 2026 Dec 31, 2025 Assets Intangible assets 0 0 Property, plant and equipment 9 11 Financial non-current assets 178,390 176,680 Total non-current assets 178,399 176,691 Total current assets 1,474 2,560 Total assets 179,873 179,251 Equity, provisions and liabilities Equity Restricted equity 2,350 2,350 Non-restricted equity 76,176 85,376 Total equity 78,526 87,726 Untaxed reserves 1,477 1,477 Provisions 812 830 Non-current liabilities 23,837 30,028 Current liabilities 75,221 59,190 Total equity, provisions and liabilities 179,873 179,251 Essity Aktiebolag (publ) Interim Report Quarter 3, 2026 18
Page 20
Notes Note 1 Accounting principles This interim report has been prepared in accordance with IAS 34 and recommendation RFR 1 of the Swedish Corporate Reporting Board and RFR 2 for the Parent company. The following amendments to IFRS® Accounting Standards have gained legal force from January 1, 2026. Essity Aktiebolag (publ) applies these amendments, which have not had any material impact on the Group’s or the Parent company’s financial statements. • IFRS 9 Financial Instruments and IFRS 7 Financial Instruments: Disclosures have been amended with regard to classification and measurement of some specific financial instruments and disclosures. • A number of other standards have been amended as part of the IASB’s annual improvement process and include clarifications, simplifications, corrections and consistency improvements. A new standard, IFRS 18 Presentation and Disclosures in Financial Statements was published on April 9, 2024, and is to be applied as of January 1, 2027. The standard includes new requirements regarding the presentation and disclosure of information in financial statements and, among other changes, introduces a new structure for the income statement with categories for operating, investing and financing activities, as well as new mandatory subtotals. The principles for aggregation and disaggregation have been clarified, and specific disclosure requirements have been introduced for management-defined performance measures (MPMs). Essity’s implementation process is ongoing and includes the structure of the future income statement, performance measures, and the required adjustments to reporting, systems and processes, as well as the preparation of comparative information. In other respects, the accounting principles and calculation methods applied correspond to those described in Essity’s 2025 Annual Report. Note 2 Risks and uncertainties Processes for risk management Essity’s Board determines the Group’s strategic direction based on recommendations from the Executive Management Team. Responsibility for the long-term, overall management of strategic risks corresponds to the company’s delegation structure, from the Board of Directors to the CEO and from the CEO to the Business Area Presidents. This means that most operational risks are managed by Essity’s business areas at the local level, but they are centrally coordinated when considered necessary. The tools used for coordination consist primarily of the business areas regular reporting and the annual strategy process, which includes risks and risk management. Essity’s financial risk management is centralized, as is its internal bank for financial transactions conducted by Group companies and the management of the Group’s energy risks. Financial risks are managed in accordance with the Group’s Finance Policy, which is adopted by Essity’s Board and, together with Essity’s Energy Risk Policy, provides a management framework. Risks are continuously compiled and monitored to ensure compliance with these guidelines. Essity has also centralized other risk management. Essity has a staff function for internal audit, which monitors compliance with the Group’s policies. Essity’s risk exposure and risk management are described on pages 41–46 in the 2025 Annual Report and in the sections under environmental information and social information on pages 58–60. No significant changes have taken place that have affected the reported risks. Risks in conjunction with company acquisitions are analyzed in the due diligence processes that Essity carries out prior to all acquisitions. In cases where acquisitions have been carried out that may affect the assessment of Essity’s risk exposure, these are described under the heading “Events during the quarter” in the interim or year- end reports. Ongoing geopolitical tensions, such as the war in Iran and the conflicts in and around the Persian Gulf, contribute to increased economic uncertainty and rising commodity prices. The prices of oil and gas have increased significantly following the outbreak of the war. Changes in prices of commodities such as oil and gas may directly or indirectly affect the Group’s financial position and operating profit as a result of higher costs, price increases and reduced purchasing power among customers and consumers. Essity Aktiebolag (publ) Interim Report Quarter 3, 2026 19
Page 21
Note 3 Financial assets and liabilities Measurement principles and classifications of financial instruments, as described in Essity’s 2025 Annual Report, Note E1, were applied consistently throughout the reporting period. Financial liabilities are measured at amortized cost provided they are not part of a fair value hedge when they are recognized at fair value through profit or loss. The fair value of trade receivables, other current and non-current receivables, cash and cash equivalents, trade payables and other current and non-current liabilities is estimated to be equal to their carrying amount. SEKm Carrying amount Fair value Carrying amount Fair value Measurement l e v e l ¹ ⁾ Sep 30, 2026 Sep 30, 2026 Dec 31, 2025 Dec 31, 2025 Assets Derivatives 2,598 2,598 506 506 2 Non-current financial assets 112 112 106 106 1 Total assets 2,710 2,710 612 612 Liabilities Derivatives 1,206 1,206 1,607 1,607 2 C u r r e n t f i n a n c i a l l i a b i l i t i e s ² ⁾ 11,881 11,881 5,707 5,707 2 N o n - c u r r e n t f i n a n c i a l l i a b i l i t i e s ² ⁾ 22,247 21,864 27,692 27,192 2 Total liabilities 35,334 34,951 35,006 34,506 1) No financial instruments have been classified to level 3. 2) The measurement level refers to liabilities measured at fair value in a hedging relationship. Note 4 The share Number of shares 2026:3 2025:3 2609 2509 Number of shares, end of period 681,945,171 693,054,489 681,945,171 693,054,489 Of which Class A shares 53,963,041 58,473,654 53,963,041 58,473,654 Of which Class B shares 627,982,130 634,580,835 627,982,130 634,580,835 Number of shares held by Essity, end of period 7,458,875 7,855,598 7,458,875 7,855,598 Number of outstanding shares before and after dilution, end of period 674,486,296 685,198,891 674,486,296 685,198,891 Average number of Class B shares held by Essity 5,283,642 5,694,757 6,085,999 5,509,224 Average number of shares before and after dilution 676,661,529 687,359,732 679,521,584 690,675,287 Note 5 Acquisitions and divestments On November 12, 2025, Essity announced that it had acquired Edgewell Personal Care’s feminine care business, including the brands Carefree, Stayfree and o.b. in North America and Playtex globally. The preliminary purchase price allocation presented in Essity’s 2025 Annual Report has subsequently been adjusted based on additional information on the opening balance of the business obtained after completion of the acquisition. The acquisition strengthens Essity’s presence in feminine care in North America and enables expected synergies, and goodwill has thus been recognized. The business has about 500 employees and reported net sales of USD 264m (SEK 2,583m) in 2025. The purchase price for the assets amounted to USD 339m (SEK 2,994m) as well as the take-over of net debt of SEK 10m. The acquisition supports Essity’s strategy to focus on categories that yield a high return and to strengthen the company’s market position in the USA, the world’s largest hygiene market. The acquisition was consolidated into Essity’s consolidated financial statements from February 2, 2026. From the date of consolidation, reported net sales amounted to SEK 1,604m, EBITDA to SEK 36m and EBITA to SEK -27m. If the acquisition had been consolidated as of January 1, 2026, net sales would have amounted to SEK 1,820m, EBITDA to SEK 49m and EBITA to SEK -23m. Acquisition costs amounted to SEK 118m and were recognized as IAC. Purchase price allocation SEKm Intangible assets 1,099 Property, plant and equipment 603 Operating assets 524 Net debt excluding cash and cash equivalents -10 Operating liabilities -85 Fair value of net assets 2,131 Goodwill 863 Consideration transferred 2,994 Consideration transferred -2,994 Acquired net debt excluding cash and cash equivalents -10 Acquisitions of Group companies and other operations during the period, including net debt assumed -3,004 Essity Aktiebolag (publ) Interim Report Quarter 3, 2026 20
Page 22
Note 5 cont. On August 19, 2026, Essity announced that it had entered into an agreement to acquire Kenvue’s feminine care business in Brazil, including the market-leading brands Carefree, Sempre Livre and o.b. The purchase price amounts to USD 284m (approximately SEK 2.7bn) on a cash and debt-free basis. The acquisition strengthens Essity’s position as a market leader in feminine care in Latin America. The transaction is still subject to regulatory approval in Brazil and other customary closing conditions as well as the completion of the Kimberly-Clark and Kenvue transaction and is expected to close during the second quarter of 2027. Note 6 Use of non-International Financial Reporting Standards (IFRS®) performance measures Guidelines for Alternative Performance Measures (APMs) for companies with securities listed on a regulated market in the EU have been issued by ESMA (European Securities and Markets Authority). These guidelines are to be applied for APMs not supported under IFRS. This interim report refers to a number of performance measures not defined in IFRS. These performance measures are used to help investors, management and other stakeholders to analyze the company’s operations. These non-IFRS performance measures may differ from similarly titled measures among other companies. Essity’s 2025 Annual Report, pages 120–124, describes the various non-IFRS performance measures that are used as a complement to the financial information presented in accordance with IFRS. Abbreviations are used in the report for the performance and return measures below. Abbreviation Complete expression EBITA Operating profit before amortization of acquisition-related intangible assets EBITDA Operating profit before depreciation and amortization of property, plant and equipment and intangible assets IAC Items affecting comparability ROCE Return on capital employed ROE Return on equity Capital employed SEKm 2609 2509 2512 Total assets 185,001 167,620 167,116 -Financial assets -16,413 -11,333 -14,235 -Non-current non-interest bearing liabilities -8,348 -7,099 -6,748 -Current non-interest bearing liabilities -37,652 -34,899 -33,550 Capital employed 122,588 114,289 112,583 Working capital SEKm 2609 2509 2512 Inventories 20,642 19,193 18,153 Trade receivables 24,109 22,425 21,332 Other current receivables 5,014 3,569 3,414 Trade payables -16,304 -14,672 -14,437 Other current liabilities -18,089 -17,744 -16,066 Other -68 45 -159 Working capital 15,304 12,816 12,237 Essity Aktiebolag (publ) Interim Report Quarter 3, 2026 21
Page 23
Note 6 cont. Net debt SEKm 2609 2509 2512 Surplus in funded pension plans 9,726 3,489 4,340 Non-current financial assets 129 124 142 Current financial assets 1,021 1,491 1,266 Cash and cash equivalents 5,537 6,229 8,487 Financial assets 16,413 11,333 14,235 Non-current financial liabilities 25,372 32,011 31,386 Provisions for pensions 2,129 2,438 2,146 Current financial liabilities 13,864 7,190 7,246 Financial liabilities 41,365 41,639 40,778 Net debt 24,952 30,306 26,543 EBITA SEKm 2026:3 2025:3 2609 2509 Operating profit 3,369 4,909 11,411 13,777 -Amortization of acquisition-related intangible assets 267 243 771 740 -Items affecting comparability (IAC) - impairment of acquisition-related intangible assets 0 0 7 -19 Operating profit before amortization and impairment of acquisition-related intangible assets (EBITA) 3,636 5,152 12,189 14,498 EBITA margin (%) 10.1 14.9 11.7 14.0 -Items affecting comparability (IAC) - cost of goods sold 608 -25 583 -3 -Items affecting comparability (IAC) - sales, general and administration 481 -71 1,241 -40 EBITA excl. IAC 4,725 5,056 14,013 14,455 EBITA margin excl. IAC (%) 13.1 14.6 13.4 13.9 EBITDA SEKm 2026:3 2025:3 2609 2509 Operating profit 3,369 4,909 11,411 13,777 -Amortization of acquisition-related intangible assets 267 243 771 740 -Depreciation/amortization 1,405 1,245 3,924 3,694 -Depreciation right-of-use asset 293 277 839 834 -Impairment 0 23 19 33 -Items affecting comparability (IAC) - impairment net 362 10 364 14 -Items affecting comparability (IAC) - impairment of acquisition-related intangible assets — — 7 -19 EBITDA 5,696 6,707 17,335 19,073 -Items affecting comparability (IAC) excluding depreciation/ amortization and impairment 727 -106 1,460 -57 EBITDA excl. IAC 6,423 6,601 18,795 19,016 Sales growth SEKm 2026:3 2025:3 2609 2509 Organic sales growth -98 329 144 1,782 Acquisitions 649 — 1,634 — Divestments — -7 — -28 E x c h a n g e r a t e e f f e c t ¹ ⁾ 870 -1,958 -1,279 -5,696 Recognized change 1,421 -1,636 499 -3,942 ¹ ⁾ Consists solely of currency translation effects Essity Aktiebolag (publ) Interim Report Quarter 3, 2026 22
Page 24
Note 7 Segment reporting Effective January 1, 2026, Essity has implemented an organizational change, simplifying its structure and creating end-to-end accountability. This aims to further enhance customer and consumer focus, while increasing speed, agility and operational efficiency throughout the Group. The change facilitates increased strategic focus on the product categories and segments with the greatest potential for profitable growth. The new organization consists of the business areas Health & Medical, Personal Care, Consumer Tissue and Professional Hygiene, with clear overall responsibility in each business area for innovation, production, marketing and sales. The former Consumer Goods business area has been split into Personal Care and Consumer Tissue. Essity’s former global units Global Marketing & Innovation and Global Supply Chain have been integrated into the four business areas. The tables below show parts of the income statement broken down by operating segment: Health & Medical, Personal Care, Consumer Tissue and Professional Hygiene. For additional information, refer to page 26. SEKm 2026:3 Health & Medical Personal Care Consumer Tissue Professional Hygiene Other operations Total Group Net sales 7,066 9,205 10,541 9,257 -9 36,060 Cost of goods sold -4,011 -5,561 -8,634 -6,407 -5 -24,618 Sales, general and administration -1,753 -2,403 -999 -1,275 -287 -6,717 Operating profit/loss before amortization of acquisition-related intangible assets (EBITA) excl. IAC 1,302 1,241 908 1,575 -301 4,725 Amortization of acquisition-related intangible assets -185 -77 -2 -5 2 -267 Operating profit excl. IAC 1,117 1,164 906 1,570 -299 4,458 Items affecting comparability (IAC) -93 -76 -702 -97 -121 -1,089 Operating profit/loss 1,024 1,088 204 1,473 -420 3,369 Share of results of associates and joint ventures 1 Financial items -275 Tax expense for the period -749 Profit for the period 2,346 SEKm 2025:3 Health & Medical Personal Care Consumer Tissue Professional Hygiene Other operations Total Group Net sales 6,883 7,927 10,656 9,183 -11 34,638 Cost of goods sold -3,866 -4,686 -8,332 -6,197 16 -23,065 Sales, general and administration -1,757 -2,131 -1,072 -1,310 -247 -6,517 Operating profit/loss before amortization of acquisition-related intangible assets (EBITA) excl. IAC 1,260 1,110 1,252 1,676 -242 5,056 Amortization of acquisition-related intangible assets -184 -54 -1 -5 1 -243 Operating profit excl. IAC 1,076 1,056 1,251 1,671 -241 4,813 Items affecting comparability (IAC) -14 -1 93 20 -2 96 Operating profit/loss 1,062 1,055 1,344 1,691 -243 4,909 Share of results of associates and joint ventures -4 Financial items -369 Tax expense for the period -1,178 Profit for the period 3,358 Essity Aktiebolag (publ) Interim Report Quarter 3, 2026 23
Page 25
SEKm 2609 Health & Medical Personal Care Consumer Tissue Professional Hygiene Other operations Total Group Net sales 20,483 26,200 31,099 26,523 -7 104,298 Cost of goods sold -11,412 -15,570 -25,070 -18,278 4 -70,326 Sales, general and administration -5,266 -6,996 -3,021 -3,786 -890 -19,959 Operating profit/loss before amortization of acquisition-related intangible assets (EBITA) excl. IAC 3,805 3,634 3,008 4,459 -893 14,013 Amortization of acquisition-related intangible assets -537 -217 -3 -15 1 -771 Operating profit excl. IAC 3,268 3,417 3,005 4,444 -892 13,242 Items affecting comparability (IAC) -246 -288 -764 -278 -255 -1,831 Operating profit/loss 3,022 3,129 2,241 4,166 -1,147 11,411 Share of results of associates and joint ventures 34 Financial items -832 Tax expense for the period -2,673 Profit for the period 7,940 SEKm 2509 Health & Medical Personal Care Consumer Tissue Professional Hygiene Other operations Total Group Net sales 20,542 23,674 32,628 26,943 12 103,799 Cost of goods sold -11,506 -13,779 -25,648 -18,383 -35 -69,351 Sales, general and administration -5,386 -6,467 -3,235 -3,946 -959 -19,993 Operating profit/loss before amortization of acquisition-related intangible assets (EBITA) excl. IAC 3,650 3,428 3,745 4,614 -982 14,455 Amortization of acquisition-related intangible assets -558 -164 -3 -16 1 -740 Operating profit excl. IAC 3,092 3,264 3,742 4,598 -981 13,715 Items affecting comparability (IAC) -1 -2 100 -1 -34 62 Operating profit/loss 3,091 3,262 3,842 4,597 -1,015 13,777 Share of results of associates and joint ventures 9 Financial items -1,075 Tax expense for the period -3,217 Profit for the period 9,494 Essity Aktiebolag (publ) Interim Report Quarter 3, 2026 24
Page 26
Other financial information Group information by quarter 2026:3 2026:2 2026:1 2025:4 2025:3 2025:2 2025:1 2024:4 2024:3 Net sales, SEKm 36,060 35,061 33,177 34,695 34,638 34,185 34,976 37,805 36,274 Organic sales growth, % -0.3 0.3 0.4 -1.1 0.9 1.9 2.1 3.9 1.9 Gross profit, SEKm 10,834 11,446 11,109 11,671 11,598 11,389 11,464 11,968 11,962 Gross profit excl. IAC, SEKm 11,442 11,445 11,085 11,695 11,573 11,401 11,474 12,074 11,826 EBITA, SEKm 3,636 4,105 4,448 5,005 5,152 4,628 4,718 4,585 5,130 EBITA excl. IAC, SEKm 4,725 4,685 4,603 5,117 5,056 4,693 4,706 4,969 5,097 Operating profit, SEKm 3,369 3,846 4,196 4,754 4,909 4,386 4,482 4,315 4,868 Profit for the period, SEKm 2,346 2,693 2,901 3,224 3,358 3,053 3,083 2,893 3,329 Operating cash flow, SEKm 5,783 2,790 4,354 4,369 5,324 1,540 3,765 3,297 6,453 ROCE, % 11.9 14.0 15.8 17.6 17.9 16.7 16.7 15.8 17.8 ROCE excl. IAC, % 15.5 16.0 16.3 18.0 17.6 16.9 16.7 17.1 17.7 Capital employed, SEKm 122,588 121,642 112,699 112,583 114,289 115,384 106,478 119,510 112,957 ROE, % 9.8 11.9 13.3 15.2 16.3 15.2 14.6 13.4 15.9 ROE excl. IAC, % 13.2 13.7 14.0 15.6 15.9 15.4 14.5 14.9 15.8 Debt/equity ratio 0.26 0.31 0.28 0.31 0.36 0.42 0.34 0.35 0.35 Equity/assets ratio, % 52.5 51.1 48.5 51.2 49.9 48.3 46.3 47.7 46.2 Net debt, SEKm 24,952 28,462 24,538 26,543 30,306 34,177 26,774 30,769 29,122 Earnings per share, SEK 3.47 3.94 4.23 4.69 4.86 4.39 4.43 4.13 4.73 Earnings per share excl. IAC, SEK 4.92 4.83 4.70 5.07 5.01 4.71 4.65 4.85 4.97 Equity per share, SEK 144 137 129 125 122 117 115 127 119 Margins (%) 2026:3 2026:2 2026:1 2025:4 2025:3 2025:2 2025:1 2024:4 2024:3 Gross profit margin 30.0 32.6 33.5 33.6 33.5 33.3 32.8 31.7 33.0 Gross profit margin excl. IAC 31.7 32.6 33.4 33.7 33.4 33.4 32.8 31.9 32.6 EBITA margin 10.1 11.7 13.4 14.4 14.9 13.5 13.5 12.1 14.1 EBITA margin excl. IAC 13.1 13.4 13.9 14.7 14.6 13.7 13.5 13.1 14.1 Operating margin 9.3 11.0 12.6 13.7 14.2 12.8 12.8 11.4 13.4 Operating margin excl. IAC 12.4 12.6 13.1 14.1 13.9 13.0 12.7 12.4 13.3 Sh of results of assocs. and JV 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Financial net margin -0.8 -0.9 -0.8 -0.9 -1.1 -1.0 -1.1 -1.1 -1.2 Profit margin 8.5 10.2 11.8 12.8 13.1 11.8 11.7 10.3 12.2 Profit margin excl. IAC 11.6 11.8 12.3 13.2 12.8 12.0 11.6 11.3 12.1 Income taxes -2.1 -2.5 -3.1 -3.5 -3.4 -3.0 -2.9 -2.7 -3.1 Income taxes excl. IAC -2.9 -3.0 -3.2 -3.6 -3.3 -3.0 -2.9 -2.8 -3.0 Net margin 6.4 7.7 8.7 9.3 9.7 8.8 8.8 7.6 9.1 Net margin excl. IAC 8.7 8.8 9.1 9.6 9.5 9.0 8.7 8.5 9.1 Essity Aktiebolag (publ) Interim Report Quarter 3, 2026 25
Page 27
Information by business area Net sales SEKm 2026:3 2026:2 2026:1 2025:4 2025:3 2025:2 2025:1 2024:4 2024:3 Health & Medical 7,066 6,918 6,499 6,926 6,883 6,723 6,936 7,417 7,127 Personal Care 9,205 8,815 8,180 7,884 7,927 7,763 7,984 8,411 8,083 Consumer Tissue 10,541 10,202 10,356 10,909 10,656 10,671 11,301 12,061 11,327 Professional Hygiene 9,257 9,127 8,139 8,961 9,183 9,003 8,757 9,923 9,729 Other -9 -1 3 15 -11 25 -2 -7 8 Group 36,060 35,061 33,177 34,695 34,638 34,185 34,976 37,805 36,274 Organic sales growth % 2026:3 2026:2 2026:1 2025:4 2025:3 2025:2 2025:1 2024:4 2024:3 Health & Medical 1.2 3.1 0.5 0.7 1.7 0.1 1.7 5.6 2.8 Personal Care 3.2 3.8 4.1 1.5 4.5 3.6 3.0 4.8 4.4 Consumer Tissue -3.0 -5.3 -3.5 -4.4 -1.9 2.9 2.7 4.3 2.0 Professional Hygiene -1.1 2.1 1.9 -0.8 0.7 0.6 0.7 1.4 -0.8 Group -0.3 0.3 0.4 -1.1 0.9 1.9 2.1 3.9 1.9 EBITA excl. IAC SEKm 2026:3 2026:2 2026:1 2025:4 2025:3 2025:2 2025:1 2024:4 2024:3 Health & Medical 1,302 1,310 1,193 1,296 1,260 1,159 1,231 1,361 1,386 Personal Care 1,241 1,131 1,262 990 1,110 1,120 1,198 1,221 1,261 Consumer Tissue 908 988 1,112 1,442 1,252 1,248 1,245 1,024 1,024 Professional Hygiene 1,575 1,573 1,311 1,750 1,676 1,525 1,413 1,817 1,812 Other -301 -317 -275 -361 -242 -359 -381 -454 -386 Group 4,725 4,685 4,603 5,117 5,056 4,693 4,706 4,969 5,097 EBITA margin excl. IAC % 2026:3 2026:2 2026:1 2025:4 2025:3 2025:2 2025:1 2024:4 2024:3 Health & Medical 18.4 18.9 18.4 18.7 18.3 17.2 17.7 18.3 19.4 Personal Care 13.5 12.8 15.4 12.6 14.0 14.4 15.0 14.5 15.6 Consumer Tissue 8.6 9.7 10.7 13.2 11.7 11.7 11.0 8.5 9.0 Professional Hygiene 17.0 17.2 16.1 19.5 18.3 16.9 16.1 18.3 18.6 Group 13.1 13.4 13.9 14.7 14.6 13.7 13.5 13.1 14.1 Capital employed SEKm 2026:3 2026:2 2026:1 2025:4 2025:3 2025:2 2025:1 2024:4 2024:3 Health & Medical 33,537 33,193 32,430 31,577 32,673 33,352 32,366 34,566 33,112 Personal Care 23,268 23,030 22,593 18,299 18,621 18,405 17,913 18,593 17,238 Consumer Tissue 37,000 36,104 35,059 34,744 35,512 35,442 34,180 36,700 35,322 Professional Hygiene 27,290 27,132 26,347 25,176 25,311 25,850 25,494 25,998 24,501 Other 1,493 2,183 - 3 , 7 3 0 ¹ ⁾ 2,787 2,172 2,335 - 3 , 4 7 5 ² ⁾ 3,653 2,784 Group 122,588 121,642 112,699 112,583 114,289 115,384 106,478 119,510 112,957 ¹ ⁾ 2 0 2 6 : 1 : O f t h i s a m o u n t , S E K 5 , 9 5 6 m r e p r e s e n t s a l i a b i l i t y r e l a t i n g t o t h e d i v i d e n d f o r E s s i t y ’ s s h a r e h o l d e r s p a i d o n A p r i l 2 , 2 0 2 6 , a s decided at the Annual General Meeting on March 26, 2026. ² ⁾ Of this amount, SEK 5,711m represents a liability relating to the dividend for Essity’s shareholders paid on April 3, 2025, as decided at the Annual General Meeting on March 27, 2025. ROCE excl. IAC % 2026:3 2026:2 2026:1 2025:4 2025:3 2025:2 2025:1 2024:4 2024:3 Health & Medical 15.6 16.0 14.9 16.1 15.3 14.1 14.7 16.1 16.5 Personal Care 21.5 19.8 24.7 21.5 24.0 24.7 26.2 27.3 28.4 Consumer Tissue 9.9 11.1 12.8 16.4 14.1 14.3 14.1 11.4 11.5 Professional Hygiene 23.2 23.5 20.4 27.7 26.2 23.8 22.0 28.8 28.7 Group 15.5 16.0 16.3 18.0 17.6 16.9 16.7 17.1 17.7 Operating cash flow SEKm 2026:3 2026:2 2026:1 2025:4 2025:3 2025:2 2025:1 2024:4 2024:3 Health & Medical 1,657 872 1,080 1,538 1,471 398 1,232 976 1,674 Personal Care 1,610 868 786 541 1,133 654 215 400 1,822 Consumer Tissue 502 413 1,460 1,297 947 506 1,442 714 971 Professional Hygiene 2,160 1,100 804 1,922 1,880 490 1,054 1,678 2,153 Other -146 -463 224 -929 -107 -508 -178 -471 -167 Group 5,783 2,790 4,354 4,369 5,324 1,540 3,765 3,297 6,453 Essity Aktiebolag (publ) Interim Report Quarter 3, 2026 26
Page 28
Invitation to presentation President and CEO Ulrika Kolsrud and Executive Vice President and CFO Fredrik Rystedt will present the report at a live webcast and teleconference at 09:00 a.m. CEST on October 22, 2026. Link to the live presentation, which can also be viewed afterwards: https://essity.videosync.fi/2026-10-22 Contact information for conference call with the possibility to ask questions: UK: +44 (0) 33 0551 02 00 USA: +1 786 697 35 01 SWE: +46 (0) 8 505 204 24 Please call in well in advance of the start of the presentation. Indicate: “Essity”. Financial calendar 2027 Report for quarter 4 and full-year 2026 January 21, 2027 Annual Report 2026 February/March, 2027 Annual General Meeting April 7, 2027 Interim report, Quarter 1, 2027 April 22, 2027 Interim report, Quarter 2, 2027 July 15, 2027 Interim report, Quarter 3, 2027 October 21, 2027 For additional information Fredrik Rystedt, Executive Vice President and CFO, tel: +46 (0) 8 788 51 31 Sandra Åberg, Vice President Investor Relations, tel: +46 (0) 70 564 96 89 Per Lorentz, Vice President Corporate Affairs, tel: +46 (0) 73 313 30 55 For more information about Essity, visit essity.com. Essity is a global, leading hygiene and health company. Every day, our products, solutions and services are used by a billion people around the world. Our purpose is to break barriers to well-being for the benefit of consumers, patients, caregivers, customers and society. Sales are conducted in approximately 150 countries under the leading global brands TENA and Tork, and other strong brands such as Actimove, Cutimed, JOBST, Knix, Leukoplast, Libero, Libresse, Lotus, Modibodi, Nosotras, Saba, Tempo, TOM Organic and Zewa. In 2025, Essity had net sales of approximately SEK 138bn (EUR 13bn) and employed 36,000 people. The company’s headquarter is in Stockholm, Sweden and Essity is listed on Nasdaq Stockholm. More information at essity.com and follow Essity on social media.